Cytodyn's potential revenue for COVID-19 (coronavi
Post# of 148184
(Total Views: 607)
Posted On: 03/06/2020 1:21:20 AM
Cytodyn's potential revenue for COVID-19 (coronavirus)
Both Taiwan and China want large amounts of leronlimab when it's proven to work with COVID-19.
With the large batch production that the CEO mentioned Samsung's cost to manufacture shouldn't be more than $25 per 700mg, the wholesale should be less than $100.
Overseas we might have a deal like Vyera with COGs +10% and 50% net sales. I would expect overseas retail to be around $600 per 700mg ($2400 total for coronavirus).
600,000 vials x $600 = $360,000,000 - 30% overhead = $252,000,000 / 2 = $144,000,000 - $25,200,000 (10% royalty net sales) = $118,800,000.
With Samsung using four bioreactors of 20 Kl capacity they should be able to produce 800,000 doses every two weeks.
Both Taiwan and China want large amounts of leronlimab when it's proven to work with COVID-19.
With the large batch production that the CEO mentioned Samsung's cost to manufacture shouldn't be more than $25 per 700mg, the wholesale should be less than $100.
Overseas we might have a deal like Vyera with COGs +10% and 50% net sales. I would expect overseas retail to be around $600 per 700mg ($2400 total for coronavirus).
600,000 vials x $600 = $360,000,000 - 30% overhead = $252,000,000 / 2 = $144,000,000 - $25,200,000 (10% royalty net sales) = $118,800,000.
With Samsung using four bioreactors of 20 Kl capacity they should be able to produce 800,000 doses every two weeks.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼